CN111544317A - Anti-aging composition cationic nano-liposome and preparation method and application thereof - Google Patents
Anti-aging composition cationic nano-liposome and preparation method and application thereof Download PDFInfo
- Publication number
- CN111544317A CN111544317A CN202010354390.8A CN202010354390A CN111544317A CN 111544317 A CN111544317 A CN 111544317A CN 202010354390 A CN202010354390 A CN 202010354390A CN 111544317 A CN111544317 A CN 111544317A
- Authority
- CN
- China
- Prior art keywords
- cationic
- lipid
- sample
- nanoliposome
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Abstract
The invention relates to an anti-aging composition cationic nano-liposome and a preparation method and application thereof, which are characterized by comprising the following components in percentage by mass: lipid: astaxanthin: flax lignan: bakuchiol: hydroxy pinacolone retinoic acid ester: cosolvent: cationic polymer: glycerol: deionized water = 7-20: 1-8: 5-10: 1-3: 1-3: 2-10: 3-6: 15-30: 10-65 parts; the lipids consist of cationic lipids and neutral lipids; the cationic polymer is a biological carbohydrate gum-polyethylene glycol (PEG) graft copolymer. The liposome simultaneously loads astaxanthin, secoisolariciresinol diglucoside, bakuchiol and hydroxy pinacolone retinoic acid ester, has the advantages of good stability, small and uniform particle size, high loading content and encapsulation rate, good skin feel and good anti-aging effect, and is convenient to add into cosmetics for use.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to an anti-aging composition cationic nano liposome and a preparation method and application thereof.
Background
The aging problem has been a focus of human attention. In recent years, the rapid development of science and technology has accelerated the progress of functional cosmetics, and from the end of 20 years, the beauty science and technology field which takes anti-aging as the leading part has become popular, and anti-aging cosmetics are also more and more popular.
Astaxanthin, secoisolariciresinol diglucoside, bakuchiol and hydroxyppinacolone retinoic acid ester are active substances which are discovered at present and have strong anti-aging capability.
Astaxanthin is the natural antioxidant with the strongest antioxidant capacity, each astaxanthin molecule has two ionone rings, and hydroxyl groups and ketone groups on the rings pass through a cell membrane when the cell membrane is protected, so that the astaxanthin molecules can penetrate through the whole cell membrane structure. The antioxidant capacity of the astaxanthin is obviously higher than that of other antioxidants, and is 1000 times of that of vitamin E and 10 times of that of beta-carotene. The anti-aging performance of astaxanthin is shown in the effects of resisting oxidation, ultraviolet rays and wrinkles, and skin cells are protected from being damaged by adverse factors such as ultraviolet rays.
The structure of secoisolariciresinol diglucoside is very similar to that of human estrogen, and can promote the synthesis of collagen in human body and inhibit the sebum secretion of sebaceous gland. The Secoisolariciresinol Diglucoside (SDG) mainly exists in the form of secoisolariciresinol diglucoside (SECO), and the SDG has strong antioxidant capacity. Therefore, the secoisolariciresinol diglucoside has certain anti-aging effect.
The bakuchiol can promote ESF-1 cell proliferation, promote expression of collagen and mRNA of matrix metalloproteinase inhibitor, and inhibit expression of mRNA of matrix metalloproteinase, thereby playing a role in resisting skin aging.
The hydroxy pinacolone retinoic acid ester is a retinol derivative, has the functions of regulating metabolism of epidermis and stratum corneum, resisting aging, reducing sebum overflow, fading epidermal pigments, preventing skin aging, preventing acne, whitening skin and fading spots and the like. The strong efficacy of retinol is ensured, the irritation is greatly reduced, and the retinol is currently used for resisting aging and preventing acne recurrence.
Research shows that the compounds have excellent and obvious effect on human body anti-aging from different mechanisms. However, all four of these actives have their own drawbacks in use. For example, astaxanthin and secoisolariciresinol diglucoside are insoluble in water, have low bioavailability, are easily oxidized under daily conditions to lose biological activity, and are difficult to store and use. The bakuchiol and the hydroxy pinacolone retinoic acid ester belong to vitamin A derivatives, have poor solubility and have certain irritation to human skin when being directly used.
The cationic liposome is a zwitterionic surfactant, has hydrophilicity and hydrophobicity, is used as a drug carrier, has a wide wrapping range, and can wrap water-soluble substances, fat-soluble substances and amphoteric substances. Cationic amphiphilic compounds, which constitute the main component of cationic liposomes, are mainly commonly used as positively charged lipids, positively charged polymers, and the like, wherein the use of polymeric carriers to modify the surface of liposomes to design more effective drug delivery systems has proven to be an effective formulation method. The cationic liposome has no immunogenicity in vivo at a certain concentration, and is safe and reliable; after the medicine is carried by the cationic liposome, the transdermal effect of the medicine on the skin can be improved, the toxic and side effects are reduced, and the curative effect of the medicine is improved and prolonged. Currently, cationic lipids commonly used for preparing cationic liposomes are mainly DOTAP ((2, 3-dioleoyl-propyl) -trimethylamine), DOTMA (N- [1- (2, 3-dioleoyl) propyl ] -N, N, N-trimethyl ammonium chloride), DODMA (1, 2-dioleol-3-dimethylamino-propane), DOAB (N, N-dimethyloctadecyl allyl ammonium bromide) and DC-Chol (cholesterol), but all of the lipids have certain cytotoxicity or the prepared cationic liposomes have the defects of poor stability and the like.
The micro-droplet technology is an important branch of the micro-fluidic technology, and is a brand new technology for controlling micro-volume liquid developed on a micro-fluidic chip. By optimizing the chip channel structure and designing the fluid driving method, the flow speed, the volume ratio, the mixing sequence, the position, the temperature and the like of each phase in the micro-channel network can be accurately controlled, then the behaviors of 2 immiscible liquids (such as water and oil, one is used as a disperse phase, the other is used as a continuous phase, and the disperse phase exists in the form of micro-droplet units) are controlled, and the functions of micro-droplet generation, driving, splitting, fusion, sorting, positioning, capturing and the like are realized by utilizing the shearing force and the surface tension effect among fluids.
Disclosure of Invention
The invention aims to solve the technical problem of providing a cationic nano liposome capable of simultaneously loading astaxanthin, secoisolariciresinol diglucoside, bakuchiol and hydroxy pinacolone visual sulfonate, a preparation method and application thereof.
In order to solve the technical problems, the invention adopts the following technical scheme: the anti-aging composition cationic nanoliposome is characterized by comprising the following components in percentage by mass: lipid: astaxanthin: flax lignan: bakuchiol: hydroxy pinacolone retinoic acid ester: cosolvent: cationic polymer: glycerol: deionized water = 7-20: 1-8: 5-10: 1-3: 1-3: 2-10: 3-6: 15-30: 10-65 parts; the lipid is prepared from cationic lipid and neutral lipid according to the mass ratio of 7-11: 9-13, wherein the cationic lipid is N- [1 (2, 3-oxygen-containing dodecyl carbamyl) propyl ] -N, N, N-trimethyl ammonium carbamate iodide (DDCTMA), N- (N ', N' -dimethyl) propyl succinic acid monocholesteryl ester monoamide (DMAPA-CHEMSH), ceramide according to the mass ratio of 3:1: 0.5-1, wherein the neutral lipid is one or more of dimyristoyl phosphatidylcholine, egg yolk lecithin, phospholipid soybean lecithin or hydrogenated lecithin; the cationic polymer is a biological carbohydrate gum-polyethylene glycol (PEG) graft copolymer.
The cosolvent is one or a mixture of ethanol, propylene glycol, dipropylene glycol and butanediol.
The composition of astaxanthin, secoisolariciresinol diglucoside, bakuchiol and hydroxyphenazone retinoic acid ester used in the invention has synergistic anti-aging effects in multiple aspects such as removing free radicals of skin through antioxidation, resisting ultraviolet irradiation damage and inflammation, regulating phytoestrogen and inhibiting the expression of matrix metalloproteinase mRNA so as to promote the synthesis of skin collagen, converting the phytoestrogen into A acid through endogenous enzymatic reaction on the skin so as to promote the propagation and growth of skin cells, and the like.
The invention also provides a preparation method of the anti-aging composition cationic nanoliposome, which is characterized by comprising the following steps: the method comprises the following steps:
a: according to the mass ratio of 7-20: 1-8: 5-10: 1-3: 1-3: 2-10: 3-6: 15-30: weighing lipoid, astaxanthin, secoisolariciresinol diglucoside, bakuchiol, hydroxy pinacolone retinoic acid ester, cosolvent, cationic polymer, glycerol and deionized water for later use 10-65; the lipid is prepared from cationic lipid and neutral lipid according to the mass ratio of 7-11: 9-13, wherein the cationic lipid is N- [1 (2, 3-oxygen dodecyl carbamyl) propyl ] -N, N, N-trimethyl ammonium carbamate iodide, N- (N ', N' -dimethyl) propyl succinic acid monocholesterol ester monoamide, ceramide according to the mass ratio of 3:1: 0.5-1, wherein the neutral lipid is one or more of dimyristoyl phosphatidylcholine, egg yolk lecithin, phospholipid soybean lecithin or hydrogenated lecithin; the cationic polymer is a biological carbohydrate gum-PEG graft copolymer;
b: b, utilizing IKA to measure lipoid, astaxanthin, secoisolariciresinol diglucoside, bakuchiol, hydroxy pinacolone retinoic acid ester and cosolvent
Stirring and mixing the mixture by a dispersion machine at the rotating speed of 500-1000rpm until the mixture is uniform to obtain clear liquid serving as an internal phase solution;
c: b, stirring and mixing the cationic polymer, the glycerol and the deionized water weighed in the step A by using an IKA dispersion machine at the rotating speed of 500-1000rpm until the mixture is uniform, and obtaining clear liquid serving as an external phase solution;
e: b, filling the internal phase solution obtained in the step B into an injector, connecting the injector to an internal phase micro-injection pump of a micro-droplet device through a PE pipe, filling the external phase solution obtained in the step C into the injector, connecting the injector to an external phase micro-injection pump of the micro-droplet device through the PE pipe, and setting an internal phase flow QiSetting the external phase flow Q at 0.5-2 mL/h01-4 mL/h, after quick flushing and exhausting, starting a micro-injection pump, collecting the liquid flowing out of the outlet end of the micro-droplet device, and filtering through a 0.8-micron filter membrane to obtain the anti-aging composition cationic nano-liposome.
The micro-droplet device is a micro-droplet technology device which integrates a chip and a collecting device and is purchased from WH-CF-05 micro-fluid control technology Co., Ltd; the built-in chip of the micro-fluidic device is a Y-shaped mixed chip, and microbeads are arranged in the main channel in the chip, so that the mixing of a material body is facilitated, and nano-liposomes with smaller and more uniform particle sizes are formed.
The micro-injection pump is a WH-SP-02 type micro-injection pump produced by Suzhou province micro-fluid control technology Limited.
The anti-aging composition cation nano liposome prepared by the invention has the loading capacity of 1-8% of astaxanthin, 5-10% of secoisolariciresinol diglucoside, 1-3% of bakuchiol and 1-3% of hydroxy pinacolone visual sulfonate, and the encapsulation rate is 85-99.5% by mass percentage.
The particle size of the cation nano liposome of the anti-aging composition prepared by the invention is less than 200 nm, and the particle size polydispersity index PDI is less than 0.15.
The surface of the cation nano liposome of the anti-aging composition prepared by the invention is positively charged, and the Zeta potential on the surface of the liposome is 30 mV-60 mV.
The anti-aging composition cation nano liposome prepared by the invention is applied to cosmetics as an effective component.
The anti-aging composition cationic nano-liposome prepared by the invention is directly added into cosmetic water, essence, skin care milk and skin care cream, and the addition amount is preferably 0.5-10%.
The surface of the cationic liposome prepared by the invention is positively charged, and the cell membrane of a human body is negatively charged under the condition of physiological neutrality (pH7.4), so that the cationic liposome is easy to generate electrostatic interaction with the negatively charged cell membrane, and has better targeting property.
The cationic lipid of the cationic liposome prepared by the invention is DDCTMA, the cationic cholesterol derivative DMAPA-CHEMS and ceramide, and the mass ratio is 3:1: 0.5-1 of compound cationic lipid. DDCTMA is a superior cationic lipid for preparing cationic liposome at present, but has cytotoxicity under a certain concentration condition. DMAPA-CHEMS is a cationic cholesterol derivative obtained by derivatizing cholesterol which is a component of natural biological cell membranes, and the derivative has the characteristics of cationic lipoid and good compatibility of cholesterol which is a component of natural cell membranes and components of cell membranes. Ceramides are one of the important components of skin lipids, of which ceramide 1, ceramide 2 and ceramide 3 are the three ceramide types most closely related to human skin aging. The cationic lipid compounded by DDCTMA, DMAPA-CHEMSH and ceramide has the characteristics of good stability and excellent compatibility of the obtained cell-compatible embedded cationic liposome.
The cationic polymer used in the cationic liposome prepared by the invention is a bioglycan-PEG graft copolymer. The biogum carbohydrate gum is a natural moisturizing agent for cosmetics, has very good biocompatibility and very good long-acting moisturizing effect on stratum corneum cells of skin. The biological carbohydrate gum-PEG graft copolymer has good biocompatibility, amphipathy and other properties, and can help to improve the stability of the cationic liposome and the slow release property and biological stability in organisms after the cationic liposome is modified by the biological carbohydrate gum-PEG graft copolymer. The polymer grafted and combined with the two is endowed with the invisible property of the liposome, the probability of removing the liposome by RES is reduced, and the acting time of epidermal cells of the liposome is prolonged, so that more active substances can be applied to human cells, and the skin cells are in a good moisturizing environment due to the excellent moisturizing performance of the bioglucose gel.
In order to prove that the anti-aging cationic nanoliposome prepared by the invention has the advantages of good stability, small and uniform particle size, high loading content, good skin feel and good anti-aging effect, the invention carries out the following tests:
experiment one: stability test of cationic nanoliposomes of anti-aging composition
The cationic lipid obtained in example 1 was replaced with single ddtma, single DOTMA, single DODMA, single DOTAP, DOTMA/DMAPA-CHEMSH/ceramide 3 in a 3:1:1 ratio, DODMA/DMAPA-CHEMSH/ceramide 3 in a 3:1 ratio, DOTAP/DMAPA-CHEMSH/ceramide 3 in a 3:1 ratio, and sample 1, sample 2, sample 3, sample 4, sample 5, sample 6, and sample 7 were prepared. In addition, the biosaccharide gum-PEG graft copolymer in example 1 was replaced with PEG alone or other natural PEG graft copolymers in which PEG was grafted to sodium hyaluronate and dextran, respectively, and samples prepared using these three cationic polymer modifications were sample 8, sample 9, and sample 10, respectively. All prepared samples were subjected to appearance to determine whether a uniform cationic liposome liquid was prepared. The samples of the successfully prepared cationic liposome liquid and the samples of example 1 were centrifuged at 10000rpm for 0, 10, 20, 30 and 40min, respectively, and the appearance change of the samples was observed.
TABLE 1 composition of cationic lipids and cationic polymers of different cationic liposomes
TABLE 2 appearance of different cationic liposomes
TABLE 3 variation of cationic nanoliposomes for different anti-aging compositions under different centrifugation conditions
From tables 1,2 and 3, it can be seen that the desired stable cationic liposomes of the anti-aging composition can be formed only if the two components, the cationic lipid, are ddtma, DMAPA-CHEMSH, ceramide 3 and the cationic polymer, a graft copolymer of bioglycan-PEG, are satisfied simultaneously.
Experiment two: particle size test of cationic nanoliposome of anti-aging composition
Fig. 1 and 2 are a transmission electron microscope image and a particle size distribution diagram of a sample of the cationic nanoliposome of the antiaging composition according to example 1 of the invention. From fig. 1 and 2, it can be known that the particle size of the cationic nanoliposome of the antiaging composition of the invention is less than 200 nm.
According to the components of the embodiment 1 of the invention, a cation nanoliposome sample 1 and a cation nanoliposome sample 2 of the anti-aging composition are prepared by a low-energy-consumption stirring method and a thin film dispersion method respectively, and then particle size analysis of the liposomes is carried out by using a Malvern particle size analyzer. The particle size of each sample measured using a malvern analyzer is as follows:
TABLE 4 average particle size, Zeta potential and polydispersity index PDI of the different test samples
From the data of the average particle size, Zeta potential and PDI in table 4, it can be seen that the cationic nanoliposome of the antiaging composition obtained by example 1 prepared according to the present invention has smaller and more uniform particle size and theoretically better stability because of the larger Zeta potential.
Experiment three: testing of loading content and encapsulation efficiency of cationic nanoliposome of anti-aging composition
According to the proportion of each component in the embodiment 1 of the invention, a low-energy-consumption stirring method and a thin film dispersion method are respectively adopted to prepare the cation nanoliposome sample 1 and the sample 2 of the anti-aging composition, the anti-aging active substances in the embodiment 1 are removed by using the preparation method of the invention, and a blank comparative sample is prepared according to the proportion of each component in the embodiment 1. The content of the anti-aging active substances on the day and one month after the preparation of the four anti-aging active substance inclusion bodies which are obtained by analysis and determination by a purple wind-solar photometer under the conventional placement at room temperature. The encapsulation efficiency of each sample was determined by ultrafiltration centrifugation. Precisely measuring 400 mu L of the anti-aging composition cation nanoliposome in an ultrafiltration centrifugal tube, centrifuging by using a high-speed refrigerated centrifuge at the centrifugation temperature of 4 ℃ and the rotation speed of 10000rpm for 30 min, putting the lower-layer filtrate of the ultrafiltration centrifugal tube into a 10 mL volumetric flask after the centrifugation is finished, and measuring the content (Wf) of the anti-aging active substances in the filtrate by using an ultraviolet spectrophotometer. The total content (Wt) of anti-aging active in 400. mu.L of nanoliposomes was also determined. The Envelope Efficiency (EE) is calculated as follows:
in the formula: EE-encapsulation efficiency; wt is the total content of astaxanthin in the system; wf-free astaxanthin content.
TABLE 5 astaxanthin content and encapsulation efficiency of different test samples
TABLE 6 different test samples of secoisolariciresinol diglucoside content and encapsulation efficiency
TABLE 7 different test samples of bakuchiol content and encapsulation efficiency
TABLE 8 content and encapsulation efficiency of hydroxy pinacolone retinoic acid ester (hydroxy pinacolone retinoic acid ester) of different test samples
From tables 5, 6, 7 and 8, it can be concluded that: the entrapment rate of the anti-aging composition cationic nano-liposome prepared by the preparation method is obviously higher than that of other liposomes prepared by two low-energy consumption methods. As can be seen from the data after 30 days of normal room temperature standing, the other two methods have poor stability and low encapsulation efficiency under the condition of high loading. Therefore, the other two methods cannot obtain the high-load anti-aging composition cationic nanoliposome.
Experiment four: skin feel testing of cationic nanoliposomes of anti-aging compositions
According to the proportions of the components in the embodiment 1 of the invention, a low-energy-consumption stirring method and a thin film dispersion method are respectively adopted to prepare the anti-aging composition cationic nanoliposome sample 1 and the anti-aging composition cationic nanoliposome sample 2, and the obtained anti-aging composition cationic nanoliposome is subjected to sensory evaluation. The sensory evaluation method was as follows: selecting 10 professional sensory evaluation testers to enter a professional testing room, cleaning the front arms with a specified facial cleaning product, wiping, and sitting still for 10 min. During this time, the inside of the two front arms was marked with a cardboard, and 45 cm by 5cm areas were secured, 2 for each arm inside. After 10min, 50 microliters of the test specimen was placed in the marked area, and the tester was allowed to spread the product in the specified area with a forefinger loop 10 times, and then tapped with the forefinger and ring finger in the specified area until the product was absorbed. After the product test was completed, the tester scored 9 attributes of spreadability, oil content, moisture, skin-contact, sticky, absorption, moisture retention, soft, and residual feeling of the product, and the scoring method used 10 points (0 point means that the test product did not have the attribute, 10 points means that the test product has the extremely strong attribute)
From table 9, it is concluded that: the anti-aging composition cationic nano-liposome prepared by the invention is more refreshing, softer, less in greasy feeling and good in skin-adhering property, and is more suitable for cosmetic products than other methods.
TABLE 9 skin feel test results for cationic nanoliposomes of different anti-aging compositions
Experiment five: anti-aging effect test of cationic nano-liposome of anti-aging composition
The actives in the components of example 1 were randomly combined, but the combined ingredients were not present in four at the same time, and the prepared sample and the sample prepared in example 1 were subjected to anti-aging efficacy testing.
TABLE 10 random combinations of actives from different samples
Note: ". o" represents the absence of the component; "√" denotes the addition of this component
Referring to the formulations of table 11, different cationic nanoliposomes prepared according to the combination of actives in table 9 were added to a cream base to investigate the efficacy of anti-wrinkle creams with cationic nanoliposomes added anti-aging compositions.
Table 11 test cream formulations
360 healthy female volunteers were selected according to the volunteer principle without history of skin diseases and cosmetic allergy. The 360 volunteers were divided into 12 groups of 30 volunteers, each group numbered as example 1, sample 2, sample 3, sample 4, sample 5, sample 6, sample 7, sample 8, sample 9, sample 10, sample 11, sample 12 and sample 13, respectively.
The subjects in the group of example 1 used the cream with the added cationic nanoliposomes of the anti-aging composition obtained in example 1 on the left face and the cream without the added cationic nanoliposomes of the anti-aging composition on the right face as blank controls, and used once in the morning and evening, followed up 4 and 8 weeks before use, for a total of 3 times, at the same time during the day, and during the test period, other products of the same type were not used. Before testing, the testee needs to clean the face, after sitting still for 20min in a constant temperature and humidity environment (room temperature 22 +/-2 ℃ and relative humidity 45 +/-5%), the skin moisture, elasticity and wrinkle conditions of the left face and the right face before, after 4 weeks and after 8 weeks of use are measured and analyzed by using a CM825 skin moisture tester, an MPA580 skin elasticity tester and a PRIMOS PICO skin wrinkle detector. By analogy, the volunteers of the sample 1 group used the cream containing sample 1, as well as sample 2, sample 3, sample 4, sample 5, sample 6, nutriment, sample 8, sample 9, sample 10, sample 11, sample 12 and sample 13.
Table 12 shows the moisturizing efficacy data of the left and right faces with different samples for different periods of time, and it can be seen from table 12 that the moisture content of the skin of the left and right faces gradually increases with the increase of the application time, and the moisture content of the skin of the left face with the cream containing example 1 is higher than that of the blank control sample of the right face. Also, the moisture content of the skin using the cream containing example 1 on the left face was significantly higher than that of the left face using the cream containing sample 1, sample 2, sample 3, sample 4, sample 5, sample 6, sample 7, sample 8, sample 9, sample 10, sample 11, sample 12 and sample 13. The cationic nanoliposome of the anti-aging composition prepared in example 1 can improve the moisture of the stratum corneum of the skin, and sufficient moisture can make the skin show a healthy state of luster and plumpness.
Table 12 different time moisture test data for left and right face
Table 13 shows the skin elasticity data for the left and right faces after different time periods using different samples, where R2 and R5 are parameters representing skin elasticity, and values closer to 1 represent better skin elasticity. As can be seen from the data in the table, R2 and R5 values of both the left and right faces increased with the increase of the use time, and R2 and R5 values of the left face were higher than those of the right face using the blank control sample, which was closer to 1, using the cream containing the cationic nanoliposome of the antiaging composition prepared according to example 1. Also, the increase in the values of R2 and R5 after use of the cream containing example 1 on the left face was significantly higher than the increase in the values of the left face using the cream containing sample 1, sample 2, sample 3, sample 4, sample 5, sample 6, sample 7, sample 8, sample 9, sample 10, sample 11, sample 12 and sample 13. It is demonstrated that the cationic nanoliposome of the anti-aging composition prepared in example 1 is effective in improving skin elasticity.
TABLE 13 elasticity test data for different time of left and right face
Table 14 shows the skin wrinkle test data for the left and right faces after different time periods using different samples, the left face was applied with a cream containing the cationic nanoliposome of the anti-aging composition, and the right face was applied with a blank control sample, wherein Sa, Sq, and SV are used to characterize the wrinkle depth, defined as the wrinkle depth factor. As can be seen from the data in the table, as the using time increases, the left face of the cream containing the cationic nanoliposome of the antiaging composition prepared in example 1 has the highest Sa and Sq reduction, and the SV negatively correlated with the severity of wrinkles increases, while the right face of 14 groups of test subjects using the blank control cream has little change in parameters, and the wrinkle test results show that the cationic nanoliposome of the antiaging composition prepared in example 1 can effectively improve the wrinkle condition of skin.
TABLE 14 wrinkle test data for different time of left and right face (3D skin test method)
The anti-wrinkle effect of the product can be comprehensively evaluated according to the wrinkle formation principle and process, skin moisture content, skin elasticity and skin wrinkle change, and the cosmetic added with the cationic nanoliposome of the anti-aging composition prepared in example 1 has a remarkable anti-wrinkle effect by combining the above test data and chart.
Experiment six: cationic liposome safety test
The cytotoxic effect of the cationic nanoliposome of the anti-aging composition prepared according to example 1 on human skin cells was examined using human epidermal cell HaCaT and human dermal cell NHDFs. Digesting and counting cells which are normally and stably cultured, paving the cells on a 96-well plate, wherein 10000 cells are in each well, forming a monolayer cell layer after 24 hours, adding culture media containing different concentrations of a test object, continuously culturing for 24 hours and 48 hours, then using a CCK-8 kit, using cells treated by the culture media without the test object as a negative control, and using an absorbance value (OD value) as a detection index to detect the relative activity of the cells treated by the test object. The relative cell activity was calculated as follows.
The results of cytotoxicity studies of epidermal cells and dermal cells using CCK-8 method on the anti-aging cationic nanoliposome solution prepared in example 1 are shown in table 15. As can be seen from table 15, the cationic nanoliposome solution of the antiaging composition prepared in example 1 at a mass concentration of 10% or less has no significant cytotoxicity (cell survival rate greater than 70%) to HaCaT cells and NHDFs cells, and when the cationic nanoliposome solution of the antiaging composition prepared in example 1 acts on epidermal cells for 48 hours, the relative survival rate of the cells is reduced, but not less than 70%, so that it does not exhibit cytotoxicity. Meanwhile, as can be seen from table 15, the cationic nanoliposome solution of the antiaging composition prepared in example 1 has an obvious proliferation promoting effect on NHDFs cells, which are major effector cells of the dermal layer of the skin and can synthesize and secrete extracellular matrices such as collagen, elastin, connexin, hyaluronic acid, etc., so that substances that promote proliferation of fibroblasts are often used as raw materials for antiaging activity, and the cationic nanoliposome solution of the antiaging composition is laterally proved to have no cytotoxicity and has antiaging effect.
TABLE 15 results of cytotoxicity study of epidermal cells and dermal cells
In conclusion, the anti-aging cationic nano-liposome prepared by the invention can simultaneously load astaxanthin, secoisolariciresinol diglucoside, bakuchiol and hydroxy pinacolone retinoic acid ester, has the advantages of good stability, small and uniform particle size, high loading content and encapsulation rate, good skin feel and good anti-aging effect, and is convenient to add into cosmetics for use.
Description of the drawings:
FIG. 1 is a transmission electron microscope image of cationic nanoliposome of the antiaging composition prepared in example 1;
fig. 2 is a particle size distribution diagram of the cationic nanoliposome of the anti-aging composition.
Detailed Description
Example 1:
a preparation method of an anti-aging composition cationic nanoliposome is characterized by comprising the following steps:
a: weighing lipoid, astaxanthin, secoisolariciresinol diglucoside, bakuchiol, hydroxy pinacolone retinoic acid ester, cosolvent, cationic polymer, glycerol and deionized water according to the mass ratio of 10:6:8:2:2:7:5:25:35 for later use; the lipoid consists of cationic lipoid and neutral lipoid in the mass ratio of 7:13, wherein the cationic lipoid is N- [1 (2, 3-oxygen dodecyl carbamyl) propyl ] -N, N, N-trimethyl ammonium carbamate iodide, N- (N ', N' -dimethyl) propyl succinic acid monocholesterol ester monoamide and ceramide in the mass ratio of 3:1: 0.5, the neutral lipid is dimyristoyl phosphatidylcholine; the cationic polymer is a biological carbohydrate gum-polyethylene glycol graft copolymer;
b: b, uniformly stirring the lipoid, the astaxanthin, the secoisolariciresinol diglucoside, the bakuchiol, the hydroxy pinacolone retinoic acid ester and the cosolvent weighed in the step A by using an IKA dispersion machine at the rotating speed of 700rpm to obtain clear liquid serving as an internal phase solution;
c: b, stirring the cationic polymer, glycerol and deionized water weighed in the step A by using an IKA dispersion machine at the rotating speed of 900rpm until the mixture is uniformly stirred to obtain clear liquid serving as an external phase solution;
e: b, filling the internal phase solution obtained in the step B into an injector, connecting the injector to an internal phase micro-injection pump of a micro-droplet device through a PE pipe, filling the external phase solution obtained in the step C into the injector, connecting the injector to an external phase micro-injection pump of the micro-droplet device through the PE pipe, and setting an internal phase flow QiSetting the external phase flow Q at 1.2 mL/h0And 2.5 mL/h, starting a micro-injection pump after quick flushing and air exhausting, collecting liquid flowing out of the outlet end of the micro-droplet device, and filtering through a 0.8-micron filter membrane to obtain the anti-aging composition cationic nano-liposome.
Analyzing and determining the prepared anti-aging composition cationic nano-liposome by using a Malvern particle size analyzer to obtain the anti-aging composition cationic nano-liposome with the average particle size of 98 nm, the PDI of 0.07 and the Zeta potential of 44 mV; the encapsulation efficiency of each active substance tested according to the method in the third experiment is as follows: 99.0% of astaxanthin, 99.5% of secoisolariciresinol diglucoside, 98.2% of bakuchiol and 98.9% of hydroxy pinacolone retinoic acid ester; and the obtained anti-aging composition cation nanoliposome solution has no phenomenon of layering or bottom precipitation after centrifugation for 10min, 20min, 30 min and 40min under the high-speed centrifugation condition of 10000rpm, so that the stability is good.
Example 2:
a lotion:
weighing phase A, phase B and phase C according to the proportion in the table, and uniformly dispersing and mixing the raw materials in the phase A at the rotating speed of 500-1500rpm of an IKA disperser; then, the weighed B phase raw materials are sequentially added into the A phase, and the two phases are uniformly mixed under the condition that the rotating speed of an IKA dispersion machine is 800-; finally, the raw materials in the phase C are sequentially put into the phase C and evenly mixed under the condition that the rotating speed of an IKA dispersion machine is 800-1500 rpm. Wherein the addition amount of the cationic nanoliposome of the anti-aging composition prepared in example 1 in the skin lotion formula is 1.0%.
Example 3
A skin cream is prepared by:
the raw materials of phase A, phase B and phase C were weighed out as in the table above. Dispersing and mixing the raw materials in the phase A uniformly at the rotating speed of 500-1500rpm of an IKA dispersing machine, and then heating to 80 ℃; then heating the weighed B-phase raw material to 82 ℃ for melting; then adding the raw material melted in the phase B into the phase A, and emulsifying under the condition that the homogenizing speed of an IKA homogenizer is 5000 rpm, wherein the emulsifying time is 5 min'; after emulsification is finished, the temperature is reduced to 50 ℃, then the raw materials in the phase C are sequentially added, and the raw materials are uniformly mixed under the condition that the rotating speed of an IKA dispersion machine is 800-1500 rpm. Wherein the addition amount of the cationic nano-liposome of the anti-aging composition prepared in the example 1 in the formula of the skin cream is 10.0%.
Example 4
A skin care lotion:
weighing the phase A, the phase B and the phase C of the raw materials according to the above table, dispersing and mixing the raw materials in the phase A uniformly at the rotating speed of 500-1500rpm of an IKA disperser, and then heating to 80 ℃; then heating the weighed B-phase raw material to 82 ℃ for melting; then adding the raw material melted in the phase B into the phase A, and emulsifying under the condition that the homogenizing speed of an IKA homogenizer is 5000 rpm, wherein the emulsifying time is 5 min'; after emulsification is finished, the temperature is reduced to 50 ℃, then the raw materials in the phase C are sequentially added, and the raw materials are uniformly mixed under the condition that the rotating speed of an IKA dispersion machine is 800-1500 rpm. Wherein, the addition amount of the cationic nano-liposome of the anti-aging composition prepared in the example 1 in the formula of the skin care emulsion is 5.0%.
Claims (5)
1. The anti-aging composition cationic nanoliposome is characterized by comprising the following components in percentage by mass: lipid: astaxanthin: flax lignan: bakuchiol: hydroxy pinacolone retinoic acid ester: cosolvent: cationic polymer: glycerol: deionized water = 7-20: 1-8: 5-10: 1-3: 1-3: 2-10: 3-6: 15-30: 10-65 parts; the lipid is prepared from cationic lipid and neutral lipid according to the mass ratio of 7-11: 9-13, wherein the cationic lipid is N- [1 (2, 3-oxygen dodecyl carbamyl) propyl ] -N, N, N-trimethyl ammonium carbamate iodide, N- (N ', N' -dimethyl) propyl succinic acid monocholesterol ester monoamide, ceramide according to the mass ratio of 3:1: 0.5-1, wherein the neutral lipid is one or more of dimyristoyl phosphatidylcholine, egg yolk lecithin, phospholipid soybean lecithin or hydrogenated lecithin; the cationic polymer is a biological carbohydrate gum-polyethylene glycol (PEG) graft copolymer.
2. The anti-aging composition cationic nanoliposome of claim 1, wherein: the cosolvent is one or a mixture of ethanol, propylene glycol, dipropylene glycol and butanediol.
3. The method for preparing the cationic nanoliposome of the antiaging composition of claim 1, wherein: the method comprises the following steps:
a: according to the mass ratio of 7-20: 1-8: 5-10: 1-3: 1-3: 2-10: 3-6: 15-30: weighing lipoid, astaxanthin, secoisolariciresinol diglucoside, bakuchiol, hydroxy pinacolone retinoic acid ester, cosolvent, cationic polymer, glycerol and deionized water for later use 10-65; the lipid is prepared from cationic lipid and neutral lipid according to the mass ratio of 7-11: 9-13, wherein the cationic lipid is N- [1 (2, 3-oxygen dodecyl carbamyl) propyl ] -N, N, N-trimethyl ammonium carbamate iodide, N- (N ', N' -dimethyl) propyl succinic acid monocholesterol ester monoamide, ceramide according to the mass ratio of 3:1: 0.5-1, wherein the neutral lipid is one or more of dimyristoyl phosphatidylcholine, egg yolk lecithin, phospholipid soybean lecithin or hydrogenated lecithin; the cationic polymer is a biological carbohydrate gum-PEG graft copolymer;
b: b, uniformly stirring and mixing the lipoid, the astaxanthin, the secoisolariciresinol diglucoside, the bakuchiol, the hydroxy pinacolone visual sulfonate and the cosolvent which are weighed in the step A at the rotating speed of 500-1000rpm by using a dispersion machine to obtain clear liquid serving as an internal phase solution;
c: stirring and mixing the cationic polymer, the glycerol and the deionized water weighed in the step A by using a dispersion machine at the rotating speed of 500-1000rpm until the mixture is uniform, and obtaining clear liquid serving as an external phase solution;
e: b, filling the internal phase solution obtained in the step B into an injector, connecting the injector to an internal phase micro-injection pump of a micro-droplet device through a PE pipe, filling the external phase solution obtained in the step C into the injector, connecting the injector to an external phase micro-injection pump of the micro-droplet device through the PE pipe, and setting an internal phase flow QiSetting the external phase flow Q at 0.5-2 mL/h01-4 mL/h, after quick flushing and exhausting, starting a micro-injection pump, collecting the liquid flowing out of the outlet end of the micro-droplet device, and filtering through a 0.8-micron filter membrane to obtain the anti-aging composition cationic nano-liposome.
4. The anti-aging composition cationic nanoliposome of claims 1 or 2 or 3 as an effective ingredient for use in cosmetics.
5. The anti-aging composition according to claim 1,2 or 3, wherein the cationic nanoliposome is directly added to astringent, essence, skin care milk and skin care cream as an effective component, and the addition amount is 0.5-10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010354390.8A CN111544317B (en) | 2020-04-29 | 2020-04-29 | Anti-aging composition cationic nano-liposome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010354390.8A CN111544317B (en) | 2020-04-29 | 2020-04-29 | Anti-aging composition cationic nano-liposome and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111544317A true CN111544317A (en) | 2020-08-18 |
| CN111544317B CN111544317B (en) | 2022-01-14 |
Family
ID=71996421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010354390.8A Active CN111544317B (en) | 2020-04-29 | 2020-04-29 | Anti-aging composition cationic nano-liposome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544317B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112957276A (en) * | 2021-02-06 | 2021-06-15 | 武汉百思凯瑞生物科技有限公司 | Multi-effect hydroxy pinacolone retinoic acid ester nano composition and preparation method and application thereof |
| CN113662878A (en) * | 2021-08-26 | 2021-11-19 | 广东丸美生物技术股份有限公司 | Lipid-containing anti-aging skin-care matrix and application thereof |
| CN116158991A (en) * | 2022-12-07 | 2023-05-26 | 陕西畅想制药有限公司 | Anti-aging whitening composition and cream containing bakuchiol and preparation method thereof |
| CN116585225A (en) * | 2023-04-20 | 2023-08-15 | 杭州未可品牌管理有限公司 | Bakuchiol micro-nano emulsion and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316603A (en) * | 2005-12-02 | 2008-12-03 | 阿彻-丹尼尔斯-米德兰公司 | Processes for obtaining lignan extracts and compositions containing the lignan extracts |
| CN103458882A (en) * | 2011-02-02 | 2013-12-18 | 尤尼根公司 | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation |
| CN103553970A (en) * | 2013-11-22 | 2014-02-05 | 大连民族学院 | Preparation method of carbamate cationic lipid and application of carbamate cationic lipid in medicine or gene delivery |
| CN107951861A (en) * | 2016-10-17 | 2018-04-24 | 南京绿叶制药有限公司 | A kind of lipid nano particle membrane material feed composition |
| CN110623858A (en) * | 2019-08-28 | 2019-12-31 | 上海克琴科技有限公司 | Preparation method and application of vitamin A nano inclusion |
-
2020
- 2020-04-29 CN CN202010354390.8A patent/CN111544317B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316603A (en) * | 2005-12-02 | 2008-12-03 | 阿彻-丹尼尔斯-米德兰公司 | Processes for obtaining lignan extracts and compositions containing the lignan extracts |
| CN103458882A (en) * | 2011-02-02 | 2013-12-18 | 尤尼根公司 | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation |
| CN103553970A (en) * | 2013-11-22 | 2014-02-05 | 大连民族学院 | Preparation method of carbamate cationic lipid and application of carbamate cationic lipid in medicine or gene delivery |
| CN107951861A (en) * | 2016-10-17 | 2018-04-24 | 南京绿叶制药有限公司 | A kind of lipid nano particle membrane material feed composition |
| CN110623858A (en) * | 2019-08-28 | 2019-12-31 | 上海克琴科技有限公司 | Preparation method and application of vitamin A nano inclusion |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112957276A (en) * | 2021-02-06 | 2021-06-15 | 武汉百思凯瑞生物科技有限公司 | Multi-effect hydroxy pinacolone retinoic acid ester nano composition and preparation method and application thereof |
| CN113662878A (en) * | 2021-08-26 | 2021-11-19 | 广东丸美生物技术股份有限公司 | Lipid-containing anti-aging skin-care matrix and application thereof |
| CN116158991A (en) * | 2022-12-07 | 2023-05-26 | 陕西畅想制药有限公司 | Anti-aging whitening composition and cream containing bakuchiol and preparation method thereof |
| CN116585225A (en) * | 2023-04-20 | 2023-08-15 | 杭州未可品牌管理有限公司 | Bakuchiol micro-nano emulsion and preparation method and application thereof |
| CN116585225B (en) * | 2023-04-20 | 2023-12-12 | 杭州未可品牌管理有限公司 | Bakuchiol micro-nano emulsion and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111544317B (en) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111544317B (en) | Anti-aging composition cationic nano-liposome and preparation method and application thereof | |
| JP4758915B2 (en) | Multilamellar liposome and production method thereof | |
| JP5706326B2 (en) | Stable unilamellar composition and method for producing the same | |
| JP7195324B2 (en) | Skin care composition for skin repair and its preparation method | |
| EP3319583A1 (en) | Compositions for topical use | |
| KR101594687B1 (en) | Nature liposome and process for the preparation thereof | |
| CN1246788A (en) | Skin care product | |
| KR20110072022A (en) | A cosmetic composition having phase transformation | |
| KR102008870B1 (en) | Cosmetic composition comprising micro algae extracts stabilized in algaesome as active ingredient | |
| KR100461458B1 (en) | Multiple layered liposome and preparation method thereof | |
| AU2018272337B2 (en) | Emulsified liposome composition and preparation method therefor | |
| KR101261388B1 (en) | Composition, Capsulation method and Cosmetic containing this capsulation for enhancing efficacy of Sodium polygamma glutamate | |
| KR20200098560A (en) | Cationic vesicle and composition thereof | |
| KR20160071921A (en) | Oil-in-water solubilized cosmetic composition comprising hydrolyzed jojoba ester oil | |
| JP4592347B2 (en) | External preparation composition | |
| JP5329489B2 (en) | External preparation composition | |
| CN117919112A (en) | Modified bakuchiol liposome with improved stability and modified by anionic hydrophilic polymer | |
| KR20150078137A (en) | Cosmetic composition for improving skin wrinkle | |
| KR20160000318A (en) | Cosmetic composition containing Fir tree oil | |
| KR102594145B1 (en) | Nanoemulsion of translucent formulation containing natural ceramide and manufacturing method thereof and manufacturing method of customized cosmetics including the same | |
| KR100501309B1 (en) | Manufacturing Method of Nano-emulsified Cosmetic Composition Containing Arbutin | |
| Güler | Study of new age liposomes: transethosomes | |
| Thorat et al. | GENERAL REVIEW ON FACE SERUM | |
| CN115487088A (en) | Cosmetic composition containing oleanolic acid and application thereof | |
| WO2022053770A1 (en) | New skin-mimicking emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |